StreetAlpha.app
Home › Stocks › IDYA

IDEAYA Biosciences, Inc. (IDYA)

Healthcare
$27.40
▼ −9.75%
LAST CLOSE · NOV 17

IDEAYA Biosciences develops precision cancer drugs aimed at the specific genetic drivers of tumors. It last closed at $27.40 on Nov 17, down 9.75% on the day. The average 12-month price target from 7 analysts is $52.43 (+91.3% from the last close), with a high of $66.00 and a low of $39.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $5.1M, the largest $2.8M.

AI Auto Pilots
Is IDYA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$36.5M
−83.0% vs a year ago
Net income
−$420.0M
−1149.6% margin
EPS (diluted)
−$4.50
Free cash flow
−$349.8M
−957.4% margin
Valuation
Market cap
$2.6B
96.7M shares
P/E
–
No P/E while losing money
Price to sales
72.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$261.5M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
96.7M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $27.9M$27.9MFY2021FY2022: $50.9M$50.9MFY2022FY2023: $23.4M$23.4MFY2023FY2024: $7.0M$7.0MFY2024FY2025: $218.7M$218.7MFY2025

From IDYA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
7 Buy0 Hold0 Sell
Each firm's latest rating on IDYA in the past 90 days
Average 12-month target
$52.43
▲ 91.3% upside

Based on 7 analysts who set a price target on IDYA in the past 90 days. The average target is $52.43, with a high of $66.00 and a low of $39.00, compared with the last close of $27.40.

Low $39.00Avg $52.43High $66.00
Blue marker: last close $27.40
Highest target$66.00
Average target$52.43
Lowest target$39.00
Latest rating changes
MizuhoMaintained
Nov 10Buy$39
CitigroupMaintained
Nov 5Buy$66
Truist SecuritiesTarget lowered
Nov 4Buy$59 → $57
GuggenheimTarget lowered
Nov 4Buy$57 → $52
WedbushTarget raised
Nov 4Buy$60 → $63
DateFirmActionRatingPrice target
Nov 10MizuhoMaintainedBuy$39
Nov 5CitigroupMaintainedBuy$66
Nov 4Truist SecuritiesTarget loweredBuy$59 → $57
Nov 4GuggenheimTarget loweredBuy$57 → $52
Nov 4WedbushTarget raisedBuy$60 → $63
Loading…

Technical Analysis

IDYA · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 18% below its 20 day and 28% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the swing low (Jun 10) at $26.81, and the nearest resistance the Pivot at $28.25.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 6.1%/day
Key levels
$42.6852 week high+55.8%
$36.33100 day average+32.6%
$35.0550 day average+27.9%
$33.81200 day average+23.4%
$32.3120 day average+17.9%
$29.97Swing high (May 27)+9.4%
$29.79Pivot R1+8.7%
$28.25Pivot+3.1%
$27.40Last close
$26.81Swing low (Jun 10)−2.2%
$26.7052 week low−2.6%
$25.85Pivot S1−5.7%
Indicators
RSI (14)29.10Oversold below 30Oversold
MACD-1.44Below its signal lineBearish
Stochastic16.8Near the bottom of its rangeOversold
ADX (14)26.7Trending down
Williams %R-91.0Oversold below −80, overbought above −20Oversold
CCI (20)-209.7Oversold below −100, overbought above 100Oversold
Rate of change−12.5%Change over 10 sessionsBearish
ATR (14)$1.68Typical daily range, 6.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IDYA

What happened before

See how IDYA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IDYA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IDYA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IDYA in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$5.1M
Largest print
$2.8M
Loading…

IDYA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▲154 buying vs 103 selling
  • ▼Held by funds -1.8 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding280285−1.8%
In funds' top 10550.0%
Held by funds104.1%105.9%−1.8 pts
New / increased32 / 12263 / 93−1.3%
Reduced / sold out69 / 3486 / 35−14.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IDYA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IDYA is in one of them and how their past IDYA trades turned out.

IDYA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IDYA in an article yet. Here's the latest on the wider market.

About IDEAYA Biosciences

IDEAYA Biosciences is a drug developer focused on cancer treatments that target specific genetic drivers of disease. Its most advanced program, darovasertib, is being studied for uveal melanoma, a rare eye cancer, and the company is also developing candidates that combine antibody drug conjugates with DNA damage response inhibitors for solid tumors. It works with partners including Pfizer and Servier, and its therapies are aimed at cancer patients. The company is based in South San Francisco, California.

Headquarters
South San Francisco, CA
Founded
2015